How do you decide if a full-time CRO is right for a PE-backed company when board wants a revenue turnaround in 2027?

Full-time CRO vs the alternatives

The board's real choice is not "CRO or no CRO" — it is a choice between three structurally different engagement models, and most boards waste weeks debating the wrong axis (title, seniority) instead of the right one (commitment length and authority scope).

The first option is the full-time, permanent CRO. This person joins as a W-2 executive, typically with a board seat or board-observer rights, a 12-24 month runway of patience baked into their offer letter, and authority over the entire revenue function — sales, marketing, and customer success. They are hired to rebuild, not patch: new compensation plans, new territory design, personnel changes in the VP of Sales and CS leadership layer, and a multi-quarter re-architecture of how the company generates and retains revenue. This option makes sense when diagnostics point to a structural problem — the go-to-market motion itself is broken, not just under-managed.

The second option is the fractional CRO. This is a part-time, multi-client advisor who spends somewhere between 8 and 20 hours a week with the company, is paid a flat monthly retainer instead of a full executive salary and benefits load, and holds no equity. Fractional engagements are diagnostic and advisory by design: audit the pipeline, fix CRM hygiene, coach the existing VP of Sales, and design (but not necessarily execute) a new compensation model. A fractional leader is the right call when the underlying sales motion is fundamentally sound but under-managed, mis-priced, or poorly forecasted — problems that respond to expertise and cadence, not headcount authority.

The third option, often overlooked, is the interim CRO — operationally different from both of the above even though the market frequently conflates it with "fractional." An interim CRO works full-time hours like a permanent hire but on a fixed, board-approved term (typically 3-9 months), often with an explicit mandate to either fix the function themselves or identify and hire their permanent successor. Interim leaders sit in the seat, run the standups, own the forecast, and have hiring/firing authority — but everyone, including the executive, treats the role as bridge capacity. This is the right model when the company needs full operational authority immediately (a permanent search would take too long) but the board isn't yet convinced the company needs — or can afford — a permanent executive.

A fourth, quieter option deserves mention because boards frequently skip it: promoting from within and backstopping with a part-time RevOps advisor. If the company already has a strong VP of Sales who lacks only forecasting rigor or systems discipline, an outside advisor focused purely on RevOps — pipeline definitions, stage-gate hygiene, forecast methodology — can sometimes solve 70% of the board's complaint without touching the leadership structure at all. This option is cheapest and fastest, but it only works when the underlying diagnosis is a systems and process gap rather than a leadership or motion gap.

The mistake most PE boards make is picking the option that matches their anxiety level rather than the diagnosis. A board under pressure from its own LPs will often reach for the most visible, most permanent-looking fix — a full-time CRO hire — even when the actual root cause is a six-week CRM cleanup and a forecast recalibration. Conversely, boards that are conflict-averse will sometimes underinvest, hiring a fractional advisor to manage a problem that actually requires firing half the sales team and rebuilding compensation from scratch, a scope of authority a part-time advisor simply does not have.

How the board should decide

The decision tree the board should actually run is a sequence of three gating questions, not a single up-or-down vote on "do we need a CRO."

The first gate is cash runway. If the company has less than 12 months of runway, a full-time CRO is close to a mistake by default, because the executive will spend a material fraction of their time supporting fundraising, board updates, and diligence conversations rather than running revenue. In that situation, a fractional or interim leader who can stabilize the number while management (and often the CEO directly) leads the capital raise is the better sequencing — bring in the permanent executive after the raise closes, when they can actually focus on the mandate they were hired for.

The second gate is whether the CEO is sales-capable and willing to delegate. If the CEO is hands-on in sales and has genuine command of the pipeline, installing a full-time CRO creates an authority collision almost immediately — the CEO will keep making the calls that should belong to the CRO, and the hire will either quit or become a figurehead within two quarters. In that scenario, an interim leader who reports to the CEO but has a direct escalation line to the board tends to work better, because the reporting structure is honest about where the real authority sits while still giving the board independent visibility.

The third gate is the nature of the fix itself: structural versus tactical. Structural problems — a compensation plan that rewards the wrong behavior, a sales process with no real qualification stage, a customer success team incentivized to reduce workload rather than retain revenue — require sustained authority over 12+ months to rebuild. Tactical problems — poor CRM hygiene, weak lead routing, an under-coached but fundamentally capable sales manager — can be fixed in a 90-day fractional or interim engagement and don't justify the cost of a permanent hire.

Running these three gates in sequence, rather than debating them simultaneously in a single meeting, keeps the board from anchoring on the most emotionally salient issue (usually "we need someone senior in the seat now") and forces the actual constraints — cash, CEO behavior, and diagnosis — to drive the outcome.

What each option costs in real numbers

Cost comparisons between these options only make sense when normalized to a monthly or annualized basis, because the headline numbers ("we're paying $18K a month" versus "we're paying a $350K salary") look wildly different until you account for hours, equity, and duration.

A full-time CRO in a PE-backed turnaround typically commands a base salary in the $250,000-$400,000 range, plus a meaningful at-risk bonus tied to EBITDA or net revenue retention (often 30-50% of base at target), plus equity that vests over three to five years — frequently structured with a partial clawback if the turnaround fails within the first 18-24 months. Fully loaded with benefits, payroll taxes, and typical executive overhead, the all-in annual cost of a full-time CRO commonly lands between $450,000 and $650,000 in year one, before equity value is realized. That cost is justified only if the engagement runs long enough — generally 18 months or more — to amortize the ramp time, which itself averages four to six months before a new CRO is operating at full effectiveness.

A fractional CRO, by contrast, is typically retained for a flat monthly fee in the $8,000-$25,000 range depending on hours committed and seniority, with no equity and no benefits load. At 10-15 hours a week, a fractional engagement costing roughly $180,000-$300,000 annualized delivers advisory bandwidth, not operating capacity — the fractional leader designs the plan but generally does not execute the day-to-day management of a large team. This makes the fractional option dramatically cheaper on paper, but the comparison is only fair if the company's problem genuinely fits within an advisory scope; using a fractional leader to attempt full operational command of a 20-plus rep sales org usually fails regardless of price.

An interim CRO sits in between, often billed similarly to a full-time salary on a prorated monthly basis (sometimes through a staffing or executive-services firm that adds a 15-25% markup) but for a fixed 3-9 month term with no long-term equity commitment. Because interim engagements are shorter, total cash outlay is frequently lower in absolute terms even though the monthly rate looks comparable to a permanent hire — a nine-month interim engagement at a $300,000 annualized rate costs roughly $225,000 total, well under the fully loaded cost of a permanent hire's first 18 months.

The number the board should actually model is not "the CRO's compensation" but "the cost of a failed turnaround attempt." A full-time CRO hired against the wrong diagnosis — for example, brought in to fix a structural comp-plan problem when the real issue was a broken product-market fit — typically produces six months of aggressive discounting to hit short-term board expectations, a subsequent churn wave, and a demoralized sales team, before the company either fires the executive or the executive quits. That failure mode routinely costs more in destroyed pipeline value, severed customer relationships, and restart time than the salary difference between a full-time and fractional engagement ever would.

Implementation details and sequencing

Once the board has picked a model, the sequencing of the first 90-120 days determines whether the hire actually produces a turnaround or simply produces motion that looks like progress.

For a full-time CRO, the first 30 days should be almost entirely diagnostic even though the board will feel pressure to see immediate action: auditing CRM data quality, mapping the actual (not documented) sales process, reviewing the compensation plan against realized behavior, and interviewing the top and bottom quartile of reps to understand why performance varies. Firing decisions made before this diagnostic window closes are frequently wrong, because the executive is often removing people who were poorly managed rather than genuinely underperforming. Days 30-90 are when personnel and compensation changes should land — replacing a weak VP of Sales if the diagnostic confirms it, restructuring comp to reduce over-reliance on discounting, and narrowing the sales team's focus to the highest-probability segment rather than spreading effort across every vertical the company has ever sold into. Beyond day 90, the executive should be building the 12-month plan for the go-to-market motion itself, which the board reviews and approves as a distinct milestone, not something folded quietly into a monthly update.

For a fractional or interim engagement, the sequencing compresses but the discipline matters even more because there's less time to recover from a misstep. Week one should establish the exact scope in writing — what the leader owns (forecast accuracy, pipeline reviews, comp plan design) versus what they explicitly do not own (day-to-day rep management, hiring authority) — because scope ambiguity is the single most common reason fractional engagements underdeliver. The cadence itself should be board-visible from day one: weekly board or operating-partner touchpoints, not monthly, so early signal on whether the engagement is working reaches the board before a full quarter is wasted. A clear 90-day checkpoint should be built into the original agreement, with an explicit decision point — extend, convert to full-time, or exit — rather than letting the engagement drift past its term.

One sequencing detail that boards frequently get backwards regardless of which model they choose: they ask the revenue leader to commit to a bookings number in the first 30 days, before the diagnostic work is complete. This forces exactly the behavior boards say they want to avoid — heavy discounting and pipeline manipulation to hit an early number — because the executive has no better lever available yet. The healthier sequencing ties the first-quarter goal to leading indicators the leader can actually influence quickly (forecast accuracy, pipeline hygiene, qualification-stage conversion) and pushes the bookings and revenue commitments to the second and third quarter, once the underlying process changes have had time to take effect. Boards that insist on immediate bookings pressure regardless of model tend to get the same outcome: short-term numbers that look fine and a churn or margin problem that surfaces two quarters later, right when the board is deciding whether to renew, convert, or replace the leader they just installed.

Related questions

How long should a board wait before firing a newly hired CRO?

At minimum through the ramp period — four to six months before full effectiveness — plus one additional quarter to see the impact of structural changes. Firing before month six almost never reflects a fair evaluation of the executive's actual work.

Should a fractional CRO ever be given equity?

Rarely, and generally only if the engagement is expected to convert to full-time. Standard fractional retainers are cash-only; introducing equity typically signals the company should instead be negotiating an interim-to-permanent structure.

Who should the interim CRO report to — the CEO or the board?

Structure the reporting line to the CEO for daily operations but give the interim leader a direct escalation channel to the board, so the board retains independent visibility without undermining the CEO's authority.

What's the single biggest predictor that a full-time CRO hire will fail?

A CEO who is unwilling to genuinely delegate sales authority. Track record and pedigree matter less than whether the org structure actually gives the new executive room to operate.

Does the size of the sales team change which option makes sense?

Yes — teams under 10 reps are frequently over-served by a full-time executive; a fractional leader working 15-20 hours a week can manage that scale effectively and the company saves the fully loaded salary difference.

FAQ

Should the board always hire a full-time CRO once revenue passes $20 million? No. Revenue size alone is a weak signal. A $20 million company with a short sales cycle and a strong VP of Sales may only need a fractional leader to fix pricing and forecasting; a smaller company with a long cycle and a weak sales leader may genuinely need full-time authority. Decide from the sales-cycle length, CEO's sales acumen, and cash runway, not the revenue line.

What happens if a full-time CRO fails to deliver a turnaround within six months? The board typically terminates the hire, but the damage often outlasts the firing — restructured compensation, personnel changes, and discounting pressure can leave the sales team and customer base worse off than before the hire. Build a 12-month performance clause with a 90-day transition notice into the contract, and consider keeping a fractional advisor on retainer as continuity insurance.

Can a fractional CRO realistically manage a sales team of 20 or more reps?

Only with a strong VP of Sales handling day-to-day management underneath them. At 10-15 hours a week, a fractional leader cannot personally coach 20 reps or run daily standups; they can design the compensation plan, audit the pipeline, and coach the existing sales manager. If that manager is weak, the fractional model breaks down and a full-time hire becomes necessary.

How does the board prevent a CRO from over-discounting to hit short-term numbers? Tie compensation to net revenue retention and gross margin, not bookings alone. Add a clawback provision tied to churn rate in the first 12 months, and require board approval for discounting beyond a set threshold (commonly around 15%) so the executive can't unilaterally trade margin for a headline number.

Is a full-time CRO the right call if the real problem is product-market fit, not sales execution? No. A CRO, full-time or otherwise, cannot sell a product the market doesn't want. If diagnostics point to a product problem, the board should prioritize product investment and use a lighter-touch fractional leader to manage the existing sales motion in the meantime, rather than paying a premium for full-time sales leadership that can't fix the underlying issue.

Does a PE-backed company need a dedicated RevOps function alongside the CRO decision? Frequently, yes. Many "sales leadership" problems the board attributes to the CRO question are actually RevOps gaps — broken forecasting, poor CRM hygiene, no consistent pipeline-stage definitions. Fixing RevOps first sometimes resolves enough of the board's concern that the CRO decision becomes lower-stakes.

Sources

• https://hbr.org/topic/subject/sales
• https://www.bain.com/insights/topics/private-equity-report/
• https://www.mckinsey.com/capabilities/growth-marketing-and-sales/our-insights
• https://www.gartner.com/en/sales
• https://www.bcg.com/capabilities/private-equity
• https://www.pehub.com
• https://www.saastr.com
• https://corporatefinanceinstitute.com/resources/valuation/private-equity-value-creation/

Related on PULSE

• How to structure CRO compensation around net revenue retention instead of bookings
• Fractional vs interim executive hiring: what PE operating partners actually evaluate
• Diagnosing whether a revenue problem is structural or tactical before hiring anyone
• Building a 90-day executive scoping document for interim revenue leaders
• RevOps fundamentals: CRM hygiene and forecast accuracy as a pre-hire diagnostic